COVID-19 vaccines: Immune correlates and clinical outcomes.

IF 4.1 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-22 DOI:10.1080/21645515.2024.2324549

Shant H Mahrokhian, Lisa H Tostanoski, Samuel J Vidal, Dan H Barouch

引用次数: 0

Abstract

Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and has required vaccine updating and boosting. Nevertheless, hospitalizations and deaths due to COVID-19 have remained low. In this review, we summarize current knowledge of immune responses that contribute to population immunity and the mechanisms how vaccines attenuate COVID-19 disease severity.

查看原文本刊更多论文

COVID-19 疫苗：免疫相关性和临床结果

由于疫苗的广泛接种和人口的自然免疫，COVID-19 导致的严重疾病已大幅减少。随着 SARS-CoV-2 变种的出现，这些变种在很大程度上可以逃避疫苗诱导的中和抗体反应，原有疫苗的效力已经减弱，需要进行疫苗更新和强化。尽管如此，COVID-19 导致的住院和死亡人数仍然很低。在这篇综述中，我们总结了目前有关免疫反应的知识，这些免疫反应有助于提高人群免疫力，以及疫苗如何减轻 COVID-19 疾病严重程度的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.